Overview of GLP-1 RAs
Comparison of Available GLP-1 RAs
Individualizing GLP-1 RA Treatment
Strategies to Improve Patient Acceptance, Tolerance, and Adherence
Kristi W. Kelley, PharmD, FCCP, BCPS, BCACP, CDCES, BC-ADM
Department of Pharmacy Practice
Auburn University Harrison College of Pharmacy
Baptist Health Foundation Center for Medical and Surgical Care
Princeton Baptist Medical Center/Brookwood Baptist Health
Christie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP
Department of Pharmacy Practice
Midwestern University College of Pharmacy
Downers Grove, Illinois
Advocate Medical Group
The purpose of this program is to provide pharmacists with up-to-date clinical data and guideline-based recommendations on the benefits and use of GLP-1 RAs in patients with T2D. This program will be presented as a live webinar, accompanied by live Q&A.
The goal of this activity is to improve the knowledge and competence of pharmacists regarding the physiologic actions and optimal use of GLP-1 RAs in patients with T2D.
The target audience for this program is pharmacists, including clinical, community, ambulatory care, and health-system pharmacists, who care for patients with type 2 diabetes, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.
Upon completion of this activity, participants should be able to:
- Identify the physiologic actions of GLP-1 RAs that contribute to metabolic, renal, and cardiovascular benefits in patients with type 2 diabetes
- Compare the available GLP-1 RAs with regard to their dosing, administration, glycemic effects, and extraglycemic benefits
- Develop treatment plans that incorporate GLP-1 RAs early in the management of diabetes based on guideline recommendations, clinical evidence, and individualized patient needs and preferences
- Devise strategies to improve patient acceptance, tolerance, and adherence to GLP-1 RA treatment
ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-206-L01-P has been assigned to this live application-based activity (initial release date 9-28-22). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. Faculty disclosures will be provided prior to the start of the CE activity.